1. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial 
Dr Anna Axelsson, MD, Kasper Iversen, MD, Niels Vejlstrup, MD, Carolyn Ho, MD, Jakob Norsk, BScMed, Lasse Langhoff, MD, Kiril Ahtarovski, MD, Pernille Corell, MD, Ole Havndrup, MD, Morten Jensen, MD, Henning Bundgaard, MD 
The Lancet Diabetes & Endocrinology 
Volume 3, Issue 2, Pages (February 2015)
DOI: /S (14)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
ACE=angiotensin-converting enzyme. ARB=angiotensin II receptor blocker. LVEF=left ventricular ejection fraction. *Not expected to adhere to study protocol because of psychiatric disorder, dementia, imprisonment, or living abroad.
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Effect of losartan on left ventricular mass between baseline and 12-month follow-up, by prespecified subgroup
Data show between-group difference in the change in left ventricular mass (error bars show 95% CIs). LV=left ventricular. LVO=left ventricular outflow tract. ASA=alcohol septal ablation.
The Lancet Diabetes & Endocrinology 2015 3, DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions